Physician profile
Danielle Melton
NPI 1831546423
$7,855.64
in general payments reported to CMS, 2019-2025
28 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $193 · 2023: $2,046 · 2024: $3,319 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,334 · Education: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,334.21 |
| Education | $328.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,303.74 | 2022-2025 | |
| Janssen Biotech, INC. | $953.25 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $763.77 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $612.56 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $589.43 | 2023-2025 | Opzelura, Opzelura |
| Ucb, INC. | $497.47 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $455.90 | 2023-2025 | |
| Galderma Laboratories, L.P. | $426.74 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $374.07 | 2022-2024 | |
| Kerecis Limited | $304.23 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Regeneron Healthcare Solutions, INC. | $283.82 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $237.63 | 2023-2024 | Ilumya, Winlevi, Blu-U |
| Novartis Pharmaceuticals Corporation | $204.48 | 2023-2025 | |
| Amgen INC. | $203.92 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $150.16 | 2024-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $81.11 | 2024 | Tremfya |
| Mallinckrodt Hospital Products INC. | $58.19 | 2025 | Acthar |
| Verrica Pharmaceuticals INC. | $57.49 | 2024 | Ycanth |
| Organon LLC | $56.07 | 2024-2025 | Vtama |
| Leo Pharma INC. | $47.90 | 2022-2024 | Adbry |
| Genentech USA, INC. | $44.68 | 2023-2025 | Xolair |
| Dermavant Sciences, INC. | $35.69 | 2024 | Vtama |
| Organogenesis INC. | $31.03 | 2023-2025 | Puraply Wound Matrix, Puraply |
| Revance Therapeutics, INC. | $23.65 | 2024 | Daxxify |
| Convatec INC. | $18.90 | 2024 | |
| Acera Surgical, INC. | $17.33 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $13.10 | 2023 | Valchlor |
| Biofrontera INC. | $9.33 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Melton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.